CRESCENT BIOPHARMA, INC. Non Peo Neo Avg Comp Actually Paid Amt
CRESCENT BIOPHARMA, INC. (CBIO) reported Non Peo Neo Avg Comp Actually Paid Amt of $6.38 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-21.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-21
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $6.38M DEF 14A · filed 2026-04-21 |
| 2024-12-31 | $472.76K DEF 14A · filed 2026-04-21 |
| 2023-12-31 | $1.04M DEF 14A · filed 2026-04-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |